Introduction Final overall survival (OS) analyses are presented for EGFR mutations and liver
or brain metastases subgroups in the phase 3 IMpower150 study (NCT02366143) …

Background Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer
(NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a …

Background Patients with relapsed small-cell lung cancer (SCLC) have few treatment
options and dismal survival. Phase I/II data show activity of nivolumab in previously treated …

Aims The objectives of this study were to (1) characterize the epidemiology of liver
metastases at the time of primary cancer diagnosis (synchronous liver metastases),(2) …

Simple Summary The liver is a common site of metastasis across multiple solid organ
malignancies. Liver metastases are a known site of treatment resistance, regardless of the …

Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key
transcription regulators have recently been proposed in cell lines and limited number of …

The present study aimed to evaluate the effect of liver metastases on the efficacy from the
combination of PD-1/PD-L1 inhibitor with chemotherapy as first-line treatment in lung cancer …

Abstract Background Bone metastases (BoM) are a negative prognostic factor in non-small-
cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ …

AIM To evaluate the prognostic value of site-specific metastases among patients with
metastatic pancreatic carcinoma registered within the Surveillance, Epidemiology and End …

Background The overall survival of patients with pancreatic cancer is extremely low. Despite
multiple large-scale studies, identification of predictors of patient survival remains …